Search

Displaying results 1451 - 1460 of 4236 in total
  1. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … Ustekinumab biosimilars are available in some markets, including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[

  2. Drug

    Carbazochrome

    go.drugbank.com/drugs/DB09012
    ApprovedWithdrawn

    It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.

  3. Drug

    Lornoxicam

    go.drugbank.com/drugs/DB06725
    ApprovedInvestigational

    Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of...

  4. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL).

  5. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic

  6. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. … It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

  7. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 re...

  8. Drug

    Diethylamino hydroxybenzoyl hexyl benzoate

    go.drugbank.com/drugs/DB11269
    Approved

    Diethylamino hydroxybenzoyl hexyl benzoate is a UV filter with high absorption in the UV-A range. Minimizing the overexposure of human skin to ultraviolet radiation that may lead to acute and chronic photodamage, diethylamino hydroxybenz...

  9. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [A222398] Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. … [A222393] Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017,[A191382] leading to considerable interest in remdesivir as a possible treatment for COVID-19.

  10. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. … [L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however.